Benzinga · Oct 2, 2026
Mangoceuticals (MGRX) Shares Fall 12% After Hours: Here's Why
Mangoceuticals shares fall 12% after hours despite a $2.5 million strategic investment in its antiviral IP subsidiary.
MG
NASDAQ · MGRX
Mangoceuticals, Inc.
Healthcare · Medical - Healthcare Information Services
$0.45
Up+$0.03 (+7.66%)
Updated Oct 7, 2026, 1:19 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 12.92M
- P/E ratio
- -0.66
- Dividend yield
- 0.00%
- 52-week range
- $0.16 – $1.25
- Volume
- 834.09K
- Avg. volume
- 1.42M
Price performance · MGRX
MGRX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
MGRX closed at $0.45 after 21 trading sessions, up 9.49% for the selected period.
- Last close
- $0.45
- Period change
- +9.49%
- Period low
- $0.38
- Period high
- $0.48
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $0.423 | $0.4564 | $0.4111 | $0.45 | 834.09K |
| Oct 5, 2026 | $0.4266 | $0.438 | $0.4092 | $0.418 | 581.37K |
| Oct 2, 2026 | $0.426 | $0.4439 | $0.426 | $0.4371 | 877.23K |
| Oct 1, 2026 | $0.4304 | $0.5199 | $0.4245 | $0.4805 | 2.13M |
| Sep 30, 2026 | $0.431 | $0.4445 | $0.4275 | $0.4281 | 209.39K |
| Sep 29, 2026 | $0.3858 | $0.459 | $0.3795 | $0.4445 | 1.14M |
| Sep 28, 2026 | $0.45 | $0.4574 | $0.37 | $0.3848 | 1.01M |
| Sep 25, 2026 | $0.452 | $0.4787 | $0.452 | $0.466 | 83.23K |
| Sep 24, 2026 | $0.4394 | $0.4795 | $0.4349 | $0.4641 | 557.62K |
| Sep 23, 2026 | $0.425 | $0.4599 | $0.4125 | $0.4489 | 408.36K |
| Sep 22, 2026 | $0.45 | $0.4571 | $0.41 | $0.4311 | 472.73K |
| Sep 21, 2026 | $0.465 | $0.48 | $0.4441 | $0.4505 | 435.58K |
| Sep 18, 2026 | $0.45 | $0.4799 | $0.3951 | $0.476 | 1.59M |
| Sep 17, 2026 | $0.445 | $0.46 | $0.4371 | $0.445 | 304.29K |
| Sep 16, 2026 | $0.43 | $0.4719 | $0.4299 | $0.4524 | 1.08M |
| Sep 15, 2026 | $0.41 | $0.44 | $0.4052 | $0.42 | 410.02K |
| Sep 14, 2026 | $0.3923 | $0.4199 | $0.385 | $0.41 | 578.34K |
| Sep 11, 2026 | $0.38 | $0.408 | $0.376 | $0.4028 | 288.1K |
| Sep 10, 2026 | $0.4035 | $0.414 | $0.38 | $0.385 | 150.58K |
| Sep 9, 2026 | $0.4198 | $0.4198 | $0.4037 | $0.416 | 194.71K |
| Sep 8, 2026 | $0.403 | $0.42 | $0.3922 | $0.411 | 278.57K |
Latest MGRX news
The latest Smart Investors Daily articles mentioning MGRX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
MGRX research
Overview
Company profile and research snapshot.
Company profile
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Oct 1, 2026
Mangoceuticals’ MangoRx IP Secures $2.5M Investment From Strategic Investors, Receives Initial $1.75M Tranche
Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common StockDALLAS, TEXAS, Oct. 01, 2026 (GLOBE NEWSWIRE) --
Benzinga · Aug 21, 2026
On Aug 19, Mangoceuticals And Nuclea Energy Terminate Business Combination Agreement; Pipe Financing Minimum Of $15M Not Raised By Aug 21, 2026; Closing Conditions Not Met
On August 19, 2026, Mangoceuticals, Inc. (the "Company" or "MGRX") and Nuclea Energy Inc. ("Nuclea") mutually agreed to terminate that certain Business Combination Agreement, dated as of July 29,
Benzinga · Aug 13, 2026
Mangoceuticals’ Merger Partner, Nuclea Energy, Enters Into Definitive Agreement With Moltex Energy To Acquire Advanced Nuclear Technology Assets; Terms Undisclosed
The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy.Asset-led transaction
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
